A 67 year old woman developed a severe adenoviral pneumonitis whilst receiving immunosuppressive therapy. She showed clinical and radiological evidence of a response to treatment with nebulised and intravenous ribavirin and intravenous pooled normal human immunoglobulin. To our knowledge this is the first time that such a therapeutic approach has been used in the treatment of a condition which normally carries a very high mortality.
A 67 year old woman with mixed essential cryoglobulinaemia and an associated glomerulonephritis was started on immunosuppressive therapy with prednisolone 30 mg daily and cyclophosphamide 100 mg daily. Fol She was commenced on continuous nebulised ribavirin (20 mg/ml ribavirin via small particle generating nebuliser) but remained critically ill. Twenty four hours later intravenous ribavirin (20 mg/kg loading dose fol- lowed by 35 mg/kg/day in divided doses for four days and 25 mg/kg/day for two days) and pooled normal human immunoglobulin (total dose 100 g over seven days) were added to her treatment. The nebuliser circuit was continuously monitored for any precipitation of ribavirin, and the circuit filters were changed frequently in accordance with standard recommendations. Her clinical condition and chest radiograph then started to improve rapidly (fig 2) and by day 7 of her admission to the ITU she required only 35% inspired oxygen. She was extubated three days later. Ribavirin was administered for a total of six days intravenously and for seven days via the nebuliser. Multiple In immunocompromised patients adenoviruses are known to cause several serious syndromes, including haemorrhagic cystitis in bone marrow and renal tranplant recipients, hepatitis in liver transplant recipients, and colitis, hepatitis, and meningoencephalitis in patients with AIDS.3 The mortality from adenoviral pneumonitis in these groups is estimated to be 60%.
Little is known about the treatment of severe adenoviral infections in either the immunocompetent or the immunocompromised host.
Isolated case reports suggest a role for nebulised ribavirin in adenoviral pneumonitis,4 and in bone marrow transplant recipients adenoviral haemorrhagic cystitis has been reported to respond to intravenous ribavirin.5
Ribavirin is a broad spectrum agent which is active in vitro against a number of DNA and RNA viruses including adenovirus.6 In the against respiratory syncytial virus, influenza, and parainfluenza.7 Intravenously, ribavirin has been used for the treatment of lassa fever and epidemic haemorrhagic fever with renal syndrome.7 Few side effects to ribavirin have been reported when it is administered via either the nebulised or intravenous routes. 7 When it is nebulised via a ventilator, care must be taken to monitor for drug precipitation in the ventilator circuit and the valve connecting the nebuliser to the inspiratory limb of the circuit. The circuit itself should be filtered in accordance with the recommendations supplied with the ribavirin small particle nebuliser.
Pooled normal human immunoglobulin has been postulated to be a rational therapy for the treatment 
